Toshihiro Miyamoto

Toshihiro Miyamoto

Kanazawa, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 302 publications

QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia.

QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia.

Journal: Future oncology (London, England)
Published: July 11, 2026

ELTS Score and Early "Warning" Define a Two-Stage Risk Framework for Failure-Free Survival in Chronic-Phase CML.

ELTS Score and Early "Warning" Define a Two-Stage Risk Framework for Failure-Free Survival in Chronic-Phase CML.

Journal: Blood advances
Published: May 12, 2026

Treatment-Free Remission and Immune Profiling after Frontline Second-Generation TKI Therapy in CML.

Treatment-Free Remission and Immune Profiling after Frontline Second-Generation TKI Therapy in CML.

Journal: Blood advances
Published: May 05, 2026

Late acquisition of BCR::ABL1 during clonal evolution of SAMD9-associated MDS with phenotypic shift from AML to B-ALL.

Late acquisition of BCR::ABL1 during clonal evolution of SAMD9-associated MDS with phenotypic shift from AML to B-ALL.

Journal: International journal of hematology
Published: April 21, 2026

Parkinsonism-like delayed neurotoxicity after idecabtagene vicleucel therapy for multiple myeloma: clinicopathological, cerebrospinal fluid, and autopsy analyses.

Parkinsonism-like delayed neurotoxicity after idecabtagene vicleucel therapy for multiple myeloma: clinicopathological, cerebrospinal fluid, and autopsy analyses.

Journal: Haematologica
Published: March 09, 2026

Quizartinib Resistance Mutations and Treatment Outcomes in Relapsed or Refractory FLT3-ITD-Positive AML.

Quizartinib Resistance Mutations and Treatment Outcomes in Relapsed or Refractory FLT3-ITD-Positive AML.

Journal: Cancer science
Published: March 09, 2026

Optimizing bone health in lymphoma survivors: denosumab superiority to alendronate for R-CHOP-like therapy (the DENOSULY phase III randomized controlled trial).

Optimizing bone health in lymphoma survivors: denosumab superiority to alendronate for R-CHOP-like therapy (the DENOSULY phase III randomized controlled trial).

Journal: Haematologica
Published: January 19, 2026

Early predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIs.

Early predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIs.

Journal: Blood advances
Published: January 13, 2026

Five-year interim analysis of J-SKI: an observational study of TKI discontinuation in patients with CML in Japan.

Five-year interim analysis of J-SKI: an observational study of TKI discontinuation in patients with CML in Japan.

Journal: International journal of hematology
Published: December 03, 2025

Dose-dependent effects of oral semaglutide on arterial stiffness and the additive role of SGLT-2 inhibitors in type 2 diabetes.

Dose-dependent effects of oral semaglutide on arterial stiffness and the additive role of SGLT-2 inhibitors in type 2 diabetes.

Journal: British journal of clinical pharmacology
Published: November 03, 2025

Frontline ATRA-ATO Therapy for Acute Promyelocytic Leukemia in Japan: Results From the Prospective Multicenter FBMTG-APL2017 Trial.

Frontline ATRA-ATO Therapy for Acute Promyelocytic Leukemia in Japan: Results From the Prospective Multicenter FBMTG-APL2017 Trial.

Journal: Cancer science
Published: October 12, 2025

A phase I/II study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia: final analysis.

A phase I/II study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia: final analysis.

Journal: Therapeutic advances in hematology
Published: September 04, 2025
Showing 1-12 of 302

Last Updated: 09/26/2026